Navigation Links
Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
Date:11/27/2012

LEXINGTON, Mass., Nov. 27, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis. AVX-470 is an anti-TNF polyclonal antibody and is the first clinical candidate to come from Avaxia's oral antibody platform. The Company expects to initiate a Phase 1b clinical trial of AVX-470 in patients with active ulcerative colitis in the near term.

"Clearance of the IND allows us to advance AVX-470 into clinical development, which furthers our goal of providing patients afflicted with inflammatory bowel disease with a promising new treatment option," stated Barbara S. Fox, CEO of Avaxia. "Because AVX-470 is delivered directly to the GI tract, it has a lower potential for systemic immunosuppression than injectable anti-TNF therapies while potentially retaining the proven benefits of anti-TNF antibody therapy for inflammatory bowel disease."

About AVX-470

Avaxia has created a technology platform and a broad patent portfolio around orally administered antibodies that affect targets in the digestive tract. AVX-470 is the first product from Avaxia's platform to reach clinical development. AVX-470 is a bovine polyclonal antibody to tumor necrosis factor (TNF), a pro-inflammatory protein that has been implicated in inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. Today, injectable anti-TNF antibodies are used as an effective treatment for many IBD patients, with about $2.5 billion in sales in 2011. However, as injected drugs, they suppress the immune system throughout the body, not just locally in the gastrointestinal (GI) tract, where the disease occurs. The potentially serious side effects resulting from this systemic immunosuppression warrant a "
'/>"/>

SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
2. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
5. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
6. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
7. South and Central America Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
8. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
9. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
10. CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
11. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... -- The legalization of medical and recreational marijuana is ... new economic driver – that has taken legislators by ... response to the will of the people about a ... a National Press Club Newsmakers news conference on Thursday, ... the area of marijuana legalization will discuss its far-reaching ...
(Date:7/14/2014)... 2014 Decision Resources Group finds that ... perceptions of emerging drugs for both oncologists and ... (50 medical oncologists and 50 hematological oncologists) and ... care organizations (MCOs), reveals that despite lower familiarity ... of payers say this designation will likely influence ...
(Date:7/14/2014)... HAMILTON, N.J. , July 14, 2014 /PRNewswire/ ... Group, LLC is pleased to announce that its ... the Association for the Assessment and Accreditation of ... humane treatment of animals in science worldwide through ... highest standards for animal care and use in ...
Breaking Medicine Technology:NPC Newsmaker Program: Interpreting smoke signals from the marijuana skirmish line 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 2Breakthrough Therapy Designation is Likely to Sway Oncologists' Confidence in An Agent and Encourage Prescribing 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2
... Accuray Incorporated, (Nasdaq:  ARAY), a global leader in the ... leading academic institutions using CyberKnife radiosurgery in breast cancer ... Southwestern and Fox Chase Cancer Center, will be presented ... for Radiation Oncology (ASTRO) in San Diego from October ...
... 30 Researchers from the University of Bari, Italy, ... creates a sustained viral response (SVR) and protects them ... to determine the long-term clinical outcomes of patients posttransplant ... (HCV) infection of the liver graft. ...
Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Along with improving vision, ... Alzheimer,s disease and other types of dementia, a new ... of life, the researchers said. "These preliminary results ... benefits for people with dementia and their loved ones, ... Case Western Reserve University and University Hospitals Case Medical ...
(Date:7/14/2014)... 2014 (HealthDay News) -- Being physically active in middle ... disease and other types of dementia, suggest the findings ... found that physical exercise at various levels, especially in ... from the Mayo Clinic, said in an Alzheimer,s Association ... are not yet conclusive. More research is needed to ...
(Date:7/14/2014)... By Amy Norton ... -- Older adults who enjoy mentally stimulating games may have ... research suggests. The study looked at the connection between ... mental acuity for adults in their 50s and 60s. ... every other day performed better on tests of memory and ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up ... run and one-mile family fun walk. The run begins ... and finishes inside Levi’s® Stadium. , Over the past ... the Mission City Community Fund. All proceeds benefit education, ... Seasoned athletes, part-time pavement-pounders and walkers are invited to ...
Breaking Medicine News(10 mins):Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Staying Active May Help Prevent Dementia 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3
... for patient ... care, ... Sutter Health hospitals currently in,bargaining have voted overwhelmingly to authorize a strike ... Nurses Organizing Committee announced today. There has,been no progress in bargaining over ...
... for humans, it offered immunity for at least 6 months ... anthrax vaccine proved highly effective in tests in mice and ... , After it was placed inside the animals, noses, the ... survived after they received injections of 1,000 times the lethal ...
... AMCS ),a leader in radiology and medical image and information ... the,Thomas Weisel Partners Healthcare Conference 2007 being held in Boston. ... -- Thursday, September 6, 2007 ... a.m. (Eastern Time), ...
... Cleveland-based The ScottCare,Corporation, a leader in ... telemetry, announced today that,the company has completed ... Rozinn Electronics, Inc., a privately-held market leader ... "We are very pleased to welcome ...
... BlueShield of South,Carolina has created a new division ... Davis to vice president in charge of the ... CEO M. Edward Sellers and is,responsible for enhancing ... a corporate-wide executive development program. "We are ...
... the September issue of The American Naturalist, Juan Carranza ... Javier Prez-Barber a (Macaulay Institute, United Kingdom) offer a ... to intense competition are born with lower survival expectancies ... smaller molars relative to their body size and ...
Cached Medicine News:Health News:Nurses Send Sutter a Clear Message 2Health News:Nurses Send Sutter a Clear Message 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2
... InterStim Therapy for Urinary Control offers ... retention and the symptoms of overactive ... significant symptoms of urgency-frequency alone or ... failed or could not tolerate more ...
... 4 Conti is a battery operated dual-channel therapy ... conditions described below. ELPHA 4 Conti also includes ... and faecal incontinence ELPHA 4 Conti provokes a ... user can feel which muscles need exercising. In ...
... Template Set is the HDR solution which ... technique. The template set consists of a ... sutured to the patient and is placed ... Grid Face Plates. The Stepper Holder is ...
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
Medicine Products: